VANCOUVER, BC, April 5, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that its joint venture company with leading Chinese biotech company Sansure Biotech Inc. ("Sansure"), Hunan Sanway SepSMART Ltd. ("SepSMART"), which is based in Changsha, China, has obtained its business license and is now formally registered in China, which marks the final step for completion of the definitive joint venture agreement (the "JV Agreement") signed on October 27, 2023.

VANCOUVER, BC, April 5, 2024 /CNW/ - Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that its joint venture company with leading Chinese biotech company Sansure Biotech Inc. ("Sansure"), Hunan Sanway SepSMART Ltd. ("SepSMART"), which is based in Changsha, China, has obtained its business license and is now formally registered in China, which marks the final step for completion of the definitive joint venture agreement (the "JV Agreement") signed on October 27, 2023.

CLICK HERE TO REGISTER

VANCOUVER, BC, March 13, 2024 /CNW/ - In a recent presentation to the US Biophysical Society in Philadelphia1, Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) CEO Dr. Bob Hancock announced how the ground-breaking use of artificial intelligence (AI) has allowed the development of new and improved treatments for biofilm infections.

VANCOUVER, BC, Feb. 27, 2024 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children. According to Dr. Rob Stenstrom, Asep's Medical Director, "Abdominal pain is one of the most common complaints we see for children in the emergency room, and so it's important that we identify the difference between simple appendicitis and perforated appendicitis quickly and accurately."

VANCOUVER, BC, Dec. 28, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that, further to its news release of December 18, 2023, it has issued 3,915,930 units (each, a "Unit") of the Company at a deemed price of $0.20 per Unit in settlement of an aggregate of $783,186 comprised of $421,000 for past services performed for the Company by certain creditors, and $362,186 for the settlement of a bona fide debt owed by the Company (the "Debt Settlement"). Each Unit consists of one common share in the capital

VANCOUVER, BC, Dec. 28, 2023 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that, further to its news release of December 18, 2023, it has issued 3,915,930 units (each, a "Unit") of the Company at a deemed price of $0.20 per Unit in settlement of an aggregate of $783,186 comprised of $421,000 for past services performed for the Company by certain creditors, and $362,186 for the settlement of a bona fide debt owed by the Company (the "Debt Settlement"). Each Unit consists of one common share in the capital of the

VANCOUVER, BC, Dec. 20, 2023 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that, further to its news release of December 18, 2023 which announced a private placement and debt settlement of up to 10,000,000 units of the Company (each, a "Unit") pursuant to the listed issuer financing exemption ("LIFE Exemption") for gross proceeds of up to $2,000,000.00 (the "LIFE Offering"), it has closed the first tranche of the LIFE Offering by: (1) issuing 2,935,000 Units at a price of $0.20 per Unit, for aggregate gross proc

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./

VANCOUVER, BC, Nov. 24, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that the Company's AI-based sepsis diagnostic technology, called SepsetER TM, has received successful patent approval in the United States. The Company received confirmation from its attorneys of its US Patent Application No. 16/279788, which has been subsequently validated in the US, representing 332 million people. This patent is in addition to the successful European and Australian patents awarded to the Company in November of 2

VANCOUVER, BC, Nov. 24, 2023 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that the Company's AI-based sepsis diagnostic technology, called SepsetER TM, has received successful patent approval in the United States. The Company received confirmation from its attorneys of its US Patent Application No. 16/279788, which has been subsequently validated in the US, representing 332 million people. This patent is in addition to the successful European and Australian patents awarded to the Company in November of 2022, wh

VANCOUVER, BC, Nov. 17, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce it is in the final stage of its approval process for the draft registration statement on Form F-1 which was filed with the U.S. Securities and Exchange Commission (the "SEC") for its planned listing and trading of common shares on the NASDAQ stock exchange.

VANCOUVER, BC, Nov. 17, 2023 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce it is in the final stage of its approval process for the draft registration statement on Form F-1 which was filed with the U.S. Securities and Exchange Commission (the "SEC") for its planned listing and trading of common shares on the NASDAQ stock exchange.

A recent study led by Asep Inc.'s Founder, Chair and CEO, Dr. Robert E. W. Hancock, concludes that there is hope for improved clinical management of COVID-19 patients by better assessing the severity of sepsis, a deadly disease that impacts many COVID-19 patients.

A recent study led by Asep Inc.'s Founder, Chair and CEO, Dr. Robert E. W. Hancock, concludes that there is hope for improved clinical management of COVID-19 patients by better assessing the severity of sepsis, a deadly disease that impacts many COVID-19 patients.

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./

VANCOUVER, BC, July 3, 2023 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce it has formally filed a confidential draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the "SEC") for its planned listing and trading of common shares on the NASDAQ stock exchange.

VANCOUVER, BC, July 3, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce it has formally filed a confidential draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the "SEC") for its planned listing and trading of common shares on the NASDAQ stock exchange.

 The New Grant Will Support Important Pre-clinical Studies

 The New Grant Will Support Important Pre-clinical Studies

VANCOUVER, BC, June 16, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce it is preparing the final draft of its NASDAQ registration statement for its planned listing and trading of its common shares on the NASDAQ stock exchange.

VANCOUVER, BC, June 16, 2023 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce it is preparing the final draft of its NASDAQ registration statement for its planned listing and trading of its common shares on the NASDAQ stock exchange.

VANCOUVER, BC, June 2, 2023 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) announces the ground-breaking use of artificial intelligence (AI) to rapidly identify infections at increased risk of severe sepsis. The method was developed by the Hancock Lab, under the guidance of Dr. Robert E.W. Hancock, Killam Professor at the University of British Columbia (UBC), and analyzes the dysfunctional immune responses involved in sepsis to identify sets of genes that help assess whether a patient will acquire severe sepsis.

VANCOUVER, BC, June 2, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) announces the ground-breaking use of artificial intelligence (AI) to rapidly identify infections at increased risk of severe sepsis. The method was developed by the Hancock Lab, under the guidance of Dr. Robert E.W. Hancock, Killam Professor at the University of British Columbia (UBC), and analyzes the dysfunctional immune responses involved in sepsis to identify sets of genes that help assess whether a patient will acquire severe sepsis.

VANCOUVER, BC, May 30, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that it has engaged Aegis Capital Corporation ("Aegis"), a New York-based investment bank, as underwriter agent for a proposed listing on the NASDAQ Stock Exchange (the "Offering").

VANCOUVER, BC, May 30, 2023 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that it has engaged Aegis Capital Corporation ("Aegis"), a New York-based investment bank, as underwriter agent for a proposed listing on the NASDAQ Stock Exchange (the "Offering").

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./

VANCOUVER, BC, Jan. 27, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce that it has signed a joint venture term sheet with a leading Chinese medical diagnostic company, Sansure Biotech Inc. (Sansure). The term sheet was signed on September 29, 2022. Both parties will continue to negotiate the specific collaboration terms toward the goal of entering into a definitive agreement in the coming months. The deal highlights the growing global interest in Asep Inc.'s early sepsis diagnostic, developed using artificial in

VANCOUVER, BC, Jan. 27, 2023 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce that it has signed a joint venture term sheet with a leading Chinese medical diagnostic company, Sansure Biotech Inc. (Sansure). The term sheet was signed on September 29, 2022. Both parties will continue to negotiate the specific collaboration terms toward the goal of entering into a definitive agreement in the coming months. The deal highlights the growing global interest in Asep Inc.'s early sepsis diagnostic, developed using artificial intellige

VANCOUVER, BC, Jan. 20, 2023 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that the directors have adopted a long-term performance incentive plan (the "Plan"), whereby the Company may grant restricted share units, performance share units or deferred share units (collectively, the "Awards"). The total common shares of the Company (each, a "Share") available for the grant of Awards is equal to ten (10%) percent of the Shares issued and outstanding in the Company at the time of grant; provided, however, that if the

Webinar Features Strategic Insights from Asep Inc.'s Senior Executives, including Founder and CEO Dr. Robert E. W. Hancock, CSO Dr. Evan Haney and COO Mr. Timothy Murphy

Webinar Features Strategic Insights from Asep Inc.'s Senior Executives, including Founder and CEO Dr. Robert E. W. Hancock, CSO Dr. Evan Haney and COO Mr. Timothy Murphy

VANCOUVER, BC, Jan. 6, 2023 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is delighted to announce the recent signing of a Letter of Intent (LOI) for a joint venture between Asep Inc. and Seaspring W.L.L. (Seaspring), a Bahrain-based international investment consultancy firm. The joint venture will be owned 50/50 between Asep Inc. and Seaspring pursuant to a definitive agreement.

VANCOUVER, BC, Jan. 6, 2023 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is delighted to announce the recent signing of a Letter of Intent (LOI) for a joint venture between Asep Inc. and Seaspring W.L.L. (Seaspring), a Bahrain-based international investment consultancy firm. The joint venture will be owned 50/50 between Asep Inc. and Seaspring pursuant to a definitive agreement.

VANCOUVER, BC, Dec. 28, 2022 /CNW/ - Trading resumes in:

VANCOUVER, BC, Dec. 28, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) at the request of IIROC the Company would like to provide clarification on the disclosure regarding the diagnostic and therapeutic technologies of the Company and its subsidiaries Sepset Biosciences Inc. ("Sepset") and ABT Innovations Inc. ("ABT") that was included in a news release dated December 23, 2022.

VANCOUVER, BC, Dec. 28, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) at the request of IIROC the Company would like to provide clarification on the disclosure regarding the diagnostic and therapeutic technologies of the Company and its subsidiaries Sepset Biosciences Inc. ("Sepset") and ABT Innovations Inc. ("ABT") that was included in a news release dated December 23, 2022.

VANCOUVER, BC, Dec. 28, 2022 /CNW/ - The following issues have been halted by IIROC:

VANCOUVER, BC, Dec. 23, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that, through its subsidiaries Sepset Biosciences Inc. ("Sepset") and ABT Innovations Inc. ("ABT"), the Company is addressing antibiotic failure on two fronts — a novel diagnostic assay that detects severe sepsis in the emergency room (ER), and a peptide technology that combats hard-to-treat infections known as biofilms.

VANCOUVER, BC, Dec. 23, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that, through its subsidiaries Sepset Biosciences Inc. ("Sepset") and ABT Innovations Inc. ("ABT"), the Company is addressing antibiotic failure on two fronts — a novel diagnostic assay that detects severe sepsis in the emergency room (ER), and a peptide technology that combats hard-to-treat infections known as biofilms.

VANCOUVER, BC, Nov. 24, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that, for recruitment, incentivization and retention purposes, it has granted to certain officers and advisors an aggregate of 1,080,000 stock options (the "Options") to purchase up to 1,080,000 common shares (each, a "Share") of the Company of which 200,000 are exercisable at a price of $0.30 per Share until September 29, 2032, 200,000 are exercisable at a price of $0.30 per Share until October 1, 2032, and 680,000 are exercisable

VANCOUVER, BC, Nov. 24, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that, for recruitment, incentivization and retention purposes, it has granted to certain officers and advisors an aggregate of 1,080,000 stock options (the "Options") to purchase up to 1,080,000 common shares (each, a "Share") of the Company of which 200,000 are exercisable at a price of $0.30 per Share until September 29, 2032, 200,000 are exercisable at a price of $0.30 per Share until October 1, 2032, and 680,000 are exercisable at a p

VANCOUVER, BC, Nov. 21, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: FSX: JJ8) is pleased to announce its common shares commenced trading on the Frankfurt Stock Exchange (FSE) on November 10, 2022, under the stock symbol FSX: JJ8. The Company's common shares will continue trading on the CSE under the stock symbol CSE: ASEP and on the OTCQB under the stock symbol OTCQB: SEPSF.

VANCOUVER, BC, Nov. 21, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: FSX: JJ8) is pleased to announce its common shares commenced trading on the Frankfurt Stock Exchange (FSE) on November 10, 2022, under the stock symbol FSX: JJ8. The Company's common shares will continue trading on the CSE under the stock symbol CSE: ASEP and on the OTCQB under the stock symbol OTCQB: SEPSF.

VANCOUVER, BC, Nov. 7, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is very pleased to announce that the Company's sepsis diagnostic technology, called SepsetER TM, has received successful patent approval in 13 European countries as well as in Australia. The Company received confirmation of its European Patent (EP) 3117030 from its patent lawyers on August 29, 2022, and this patent was subsequently validated in Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland and the UK, rep

VANCOUVER, BC, Nov. 7, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is very pleased to announce that the Company's sepsis diagnostic technology, called SepsetER TM, has received successful patent approval in 13 European countries as well as in Australia. The Company received confirmation of its European Patent (EP) 3117030 from its patent lawyers on August 29, 2022, and this patent was subsequently validated in Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland and the UK, representi

VANCOUVER, BC, Oct. 17, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is very pleased to announce that it has signed a Feasibility Study Agreement with the Chinese firm Bohai Biomedical Technology Development Co. Ltd., (Bohai Biomedical).

VANCOUVER, BC, Oct. 17, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is very pleased to announce that it has signed a Feasibility Study Agreement with the Chinese firm Bohai Biomedical Technology Development Co. Ltd., (Bohai Biomedical).

VANCOUVER, B.C, Oct. 5, 2022 /PRNewswire/ -  Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is delighted to announce the appointment of Jacqueline Tucker as Chief Financial Officer (CFO) effective October 1, 2022.

VANCOUVER, B.C, Oct. 5, 2022 /CNW/ -  Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is delighted to announce the appointment of Jacqueline Tucker as Chief Financial Officer (CFO) effective October 1, 2022.

VANCOUVER, BC, Sept. 29, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce the appointment of Dr. Richard Heinzl to the Company's board of directors effective immediately.

VANCOUVER, BC, Sept. 29, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce the appointment of Dr. Richard Heinzl to the Company's board of directors effective immediately.

Asep Inc. supports World Sepsis Day (September 13th) and announces the development of a test kit to identify severe sepsis, the leading cause of death and morbidity in pandemics

Asep Inc. supports World Sepsis Day (September 13th) and announces the development of a test kit to identify severe sepsis, the leading cause of death and morbidity in pandemics

VANCOUVER, BC, July 5, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) has appointed Dr. Robert E. W. Hancock, the Co-Founder of Asep Inc, as the CEO and Chairman of the Company effective immediately. Dr. Hancock replaces Rudy Mazzocchi, the former CEO and Chairman, who has stepped down due to health reasons. Dr. Hancock states, "We wish Rudy well and sincerely thank him for his service and invaluable contributions to the Company."

Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23rd. Individual investors,...

VANCOUVER, BC, June 13, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce that the Company has received an official allowance of its patent claims that serve as the foundation underlying their first-generation sepsis diagnostic technology, SepsetER. The patent further supports the development of the innovative sepsis diagnostic technology in the European marketplace. In addition to the granting of the patent in the EU, the Company plans to validate the patent in Belgium, Denmark, Finland, France, Germany, Ireland,

VANCOUVER, BC, June 13, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce that the Company has received an official allowance of its patent claims that serve as the foundation underlying their first-generation sepsis diagnostic technology, SepsetER. The patent further supports the development of the innovative sepsis diagnostic technology in the European marketplace. In addition to the granting of the patent in the EU, the Company plans to validate the patent in Belgium, Denmark, Finland, France, Germany, Ireland, Italy,

Toronto, Ontario--(Newsfile Corp. - Le 7 juin/June 2022) - Effective immediately, ASEP Medical Holdings Inc. will be reinstated for trading.

VANCOUVER, BC, June 7, 2022 /CNW/ - Trading resumes in:

VANCOUVER, BC, June 7, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) announces that it received a Revocation Order for the Failure-to-File Cease Trade Order (FFCTO) from the British Columbia Securities Commission (BCSC) on June 1, 2022. The Company filed the necessary continuous disclosure documents required under the legislation and is legally authorized to continue trading its shares on the Canadian Securities Exchange (CSE).

VANCOUVER, BC, June 7, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) announces that it received a Revocation Order for the Failure-to-File Cease Trade Order (FFCTO) from the British Columbia Securities Commission (BCSC) on June 1, 2022. The Company filed the necessary continuous disclosure documents required under the legislation and is legally authorized to continue trading its shares on the Canadian Securities Exchange (CSE).

VANCOUVER, BC, May 11, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) announces that, due to unexpected delays in compiling the information required to prepare the Annual Filings due to: (i) a temporary lack of available resources with the Company's auditors due to COVID-19 and staff changes; and (ii) incorporating the accounting of the Company's wholly-owned subsidiary and two majority-owned subsidiaries, acquired in November 2021, it was unable to file its annual financial statements, management's discussion and analysis and the req

VANCOUVER, BC, May 11, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) announces that, due to unexpected delays in compiling the information required to prepare the Annual Filings due to: (i) a temporary lack of available resources with the Company's auditors due to COVID-19 and staff changes; and (ii) incorporating the accounting of the Company's wholly-owned subsidiary and two majority-owned subsidiaries, acquired in November 2021, it was unable to file its annual financial statements, management's discussion and analysis and the required c

Toronto, Ontario--(Newsfile Corp. - Le 10 mai/May 2022 ) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules. Cease Trade Orders have been issued by one or more securities commissions.

VANCOUVER, BC, May 10, 2022 /CNW/ - The following issues have been halted by IIROC:

VANCOUVER, BC, April 21, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce its recent successful listing on the OTCQB Venture Market in the US. The Company will be trading under the stock symbol OTCQB: SEPSF and will continue to sell its common shares on the CSE under the stock symbol CSE: ASEP. Asep Inc. will officially commence trading on the OTCQB as of the market opening today.

VANCOUVER, BC, April 21, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce its recent successful listing on the OTCQB Venture Market in the US. The Company will be trading under the stock symbol OTCQB: SEPSF and will continue to sell its common shares on the CSE under the stock symbol CSE: ASEP. Asep Inc. will officially commence trading on the OTCQB as of the market opening today.

The report concludes that a sepsis diagnostic assay could save US hospitals up to $22 billion per year.

The report concludes that a sepsis diagnostic assay could save US hospitals up to $22 billion per year.

Webinar Features Strategic Insights from Asep Inc.'s Senior Executives

Webinar Features Strategic Insights from Asep Inc.'s Senior Executives

VANCOUVER, BC, Feb. 16, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs, including both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis, as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections. The Company announces that its novel antibiofilm peptide technology is in advanced development through its collaboration with its pre-clinical partner, iFyber, LLC, and grant

VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs, including both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis, as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections. The Company announces that its novel antibiofilm peptide technology is in advanced development through its collaboration with its pre-clinical partner, iFyber, LLC, an

VANCOUVER, BC, Feb. 2, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) is pleased to announce that it has finalized an exclusive licensing arrangement with UBC for a patented and potentially groundbreaking AI-driven sepsis diagnosis technology. The technology, developed under the direction of leading UBC microbiologist and the Company's Founding Director and COO, Dr. Robert E.W. Hancock, enables early and accurate diagnosis of the deadly disease sepsis, which caused 11 million deaths globally in 20171 and is also a major contributing factor in COVID-

VANCOUVER, BC, Jan. 26, 2022 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) is pleased to announce the addition of two new high-profile members to its advisory board. The additions include Dr. Christopher S. Mow, Associate Chief of Staff and Clinical Professor of Orthopaedic Surgery at Stanford University Medical Center, and Mr. Patrick McBride, a veteran investment banker who also holds a H.BSc in neuroscience from the University of Toronto.

Vancouver, British Columbia--(Newsfile Corp. - November 19, 2021) - ASEP Medical Holdings Inc. (CSE: ASEP) (the "Company") is pleased to announce that the Canadian Securities Exchange (the "CSE") has approved the listing of the Company's common shares (collectively, the "Shares") on the CSE (the "Listing") and expects that its Shares will commence trading on the CSE at market open on Monday, November 22, 2021 under the symbol "ASEP." In connection with the Listing, the Company has obtained a receipt for its final prospectus (the "Prospectus") from the securities regulatory authorities in the provinces of British Columbia, Alberta, Ontario, New Brunswick and Saskatchewan. A copy of the Prospectus is available under the Company's profile on SEDAR.

Toronto, Ontario--(Newsfile Corp. - Le 18 novembre/November 2021) The common shares of ASEP Medical Holdings Inc. have been approved for listing on the CSE.